EXCLUSIVE: Vivani Medical's Type 2 Diabetes Treatment NPM-119 Subdermal Implant's NDA Gains FDA Clearance For Clinical Use [Yahoo! Finance]
Vivani Medical, Inc. (VANI)
Company Research
Source: Yahoo! Finance
This study will assess the safety, tolerability, and pharmacokinetics of Vivani's innovative six-month GLP-1 implant, designed to treat type 2 diabetes. LIBERATE-1 is a 12-week randomized trial designed to evaluate the safety, tolerability, and pharmacokinetics of NPM-119 in patients with type 2 diabetes. Participants in this study will discontinue their existing GLP-1 therapy to either receive NPM-119 or a comparator drug. VANI anticipates launching LIBERATE-1 in the second half of the year. Vivani is advancing its portfolio of unique drug implants using its NanoPortal technology. These implants aim to improve medication adherence and outcomes in chronic diseases like type 2 diabetes and chronic weight management. “Today marks a significant milestone for Vivani as we transition to a clinical-stage company with a promising drug candidate that has the potential to address medication non-adherence, which affects approximately 50% of patients with type 2 diabetes. LIBERATE-1 rep
Show less
Read more
Impact Snapshot
Event Time:
VANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VANI alerts
High impacting Vivani Medical, Inc. news events
Weekly update
A roundup of the hottest topics
VANI
News
- Vivani Medical obtains Australian approval to begin GLP-1 implant trial [Yahoo! Finance]Yahoo! Finance
- Vivani Medical Receives Regulatory Approval to Initiate First in Human Clinical Trial with GLP-1 Implant in Obese and Overweight Individuals in AustraliaBusiness Wire
- Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024 [Yahoo! Finance]Yahoo! Finance
- Vivani Medical to Present at the Emerging Growth Conference on September 25, 2024Business Wire
- Vivani Medical Announces Positive Preclinical Liver Fat Results with Miniature, Ultra Long-Acting GLP-1 ImplantBusiness Wire
VANI
Sec Filings
- 10/3/24 - Form 4
- 9/26/24 - Form 8-K
- 9/23/24 - Form 8-K
- VANI's page on the SEC website